# Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

> **NCT07535710** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 37 (estimated)

## Conditions studied

- Cutaneous T-Cell Lymphoma Refractory
- Cutaneous T-Cell Lymphoma, Relapsed
- Sezary Syndrome
- Cutaneous T Cell Lymphoma (CTCL)

## Interventions

- **DRUG:** Aclarubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT07535710
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07535710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07535710, "Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07535710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*